PharmiWeb

U.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)

KYGEVVI® (doxecitine and doxribtimine) powder for oral solution (2g/2g) is approved for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with an age of symptom ...
GEN - Genetic Engineering and Biotechnology News

FDA Approves First Treatment for Rare Thymidine Kinase 2 Deficiency

FDA approved KYGEVVI, the first and only treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients.

Rigel Announces One Oral and Four Poster Presentations at the 67th American Society of Hematology Annual Meeting and Exposition

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and ...
CURE

Hernexeos Effective in HER2-Mutated NSCLC

In August 2025, the FDA gave accelerated approval to Hernexeos for patients with previously treated metastatic or ...
Pulmonology Advisor

FDA Approves Kygevvi for Thymidine Kinase 2 Deficiency

The FDA has approved Kygevvi (doxecitine and doxribtimine) for the treatment of TK2d in adults and pediatric patients with an age of symptom onset on or before 12 years.